Vesair Balloon Confirmatory Trial (VECTOR)

Not Applicable

Terminated

• Conditions: Stress Urinary Incontinence
• Interventions: Device: Vesair Balloon

• Registration Number: NCT03794206
• Lead Sponsor: Solace Therapeutics, Inc.

Brief Summary

Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the subject has provided informed consent and determination that all study entry criteria have been met.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-01-03
• Study First Submitted QC: 2019-01-03
• Study First Posted: 2019-01-04
• Study Start: 2019-02-11
• Primary Completion: 2019-08-26
• Study Completion: 2022-04-28
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-10
• Last Update Posted: 2022-06-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

• Previously treated with Vesair Balloon within the past 4 years
• Normal voiding function
• Has signed consent
• Willing to undergo cystoscopy
• Available for minimum of 12 months

Exclusion Criteria

• Last Menstrual Period within past 4 years
• Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
• History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
• Urinary incontinence of neurogenic etiology.
• Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
• Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
• Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
• Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
• History of recurrent (>1) kidney stones, or one kidney stone within the past 5 years.
• History of an artificial urinary sphincter.
• Presence of gross hematuria and/or blood clots in the urine.
• History of interstitial or follicular cystitis or other painful bladder syndrome.
• Cystocele verified as Stage 3 or higher by PoP-Q Classification.
• Local genital skin infection.
• Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
• Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
• Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
• Non-ambulatory, bedridden or physically unable to complete test exercises.
• History of recent alcoholism or illicit drug abuse within the last year.
• Immunologically suppressed or immunocompromised.
• History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
• Uncontrolled diabetes (persistent A1C levels >9 percent).
• History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
• Morbid obesity, defined as BMI ≥40.0.
• History of any autoimmune or connective tissue disease or disorder that could impact bladder function

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment Arm	Vesair Balloon	Single-arm of subjects who receive treatment with Vesair Balloon

Primary Outcome Measures

Name	Time	Method
Provocative Pad Weight	3 months	in-office Pad weight test

Trial Locations

Locations (7)

Chesapeake Urology; 🇺🇸 Owings Mills, Maryland, United States

Washington Urology; 🇺🇸 Kirkland, Washington, United States

WomanCare; 🇺🇸 Arlington Heights, Illinois, United States

Urology of Virginia; 🇺🇸 Virginia Beach, Virginia, United States

Women and Infants dept of Urogynecology; 🇺🇸 Providence, Rhode Island, United States

Premier Medical Group of the Hudson Valley; 🇺🇸 Poughkeepsie, New York, United States

Regional Urology; 🇺🇸 Shreveport, Louisiana, United States